Liquid Biopsy in Breast Cancer

Overview

Journal Geburtshilfe Frauenheilkd

Specialty Gynecology & Obstetrics

Date 2020 Nov 11

PMID 33173237

Citations 10

Authors

Maggie Banys-Paluchowski

Natalia Krawczyk

Tanja Fehm

Affiliations

Soon will be listed here.

Abstract

In recent years, the blood-based analysis of circulating tumour cells (CTCs) and nucleic acids (DNA/RNA), otherwise known as liquid biopsy, has become increasingly important in breast cancer. Numerous trials have already underscored the high prognostic significance of CTC detection in both early and metastatic stages. Moreover, the changes in CTC levels and circulating tumour DNA (ctDNA) during the course of the disease correlate with the response to treatment. Research currently focuses on liquid-biopsy based therapeutic interventions in metastatic breast cancer. In this context, alpelisib, a PI3K inhibitor, was the first agent to be approved by FDA and EMA.

Citing Articles

Determination of the androgen receptor status of disseminated tumor cells in primary breast cancer patients.

Krawczyk N, Jaeger B, Martina P, Cristina L, Melissa N, Maggie B Arch Gynecol Obstet. 2023; 309(4):1525-1533.

PMID: 37902839 PMC: 10894135. DOI: 10.1007/s00404-023-07225-z.

Identification of hsa-miR-619-5p and hsa-miR-4454 in plasma-derived exosomes as a potential biomarker for lung adenocarcinoma.

Feng L, Feng Z, Hu J, Gao J, Li A, He X Front Genet. 2023; 14:1138230.

PMID: 37252659 PMC: 10213947. DOI: 10.3389/fgene.2023.1138230.

Diagnostic Potential of Circulating Tumor Cells, Urinary MicroRNA, and Urinary Cell-Free DNA for Bladder Cancer: A Review.

Koguchi D, Matsumoto K, Shiba I, Harano T, Okuda S, Mori K Int J Mol Sci. 2022; 23(16).

PMID: 36012417 PMC: 9409245. DOI: 10.3390/ijms23169148.

Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine.

Derouane F, van Marcke C, Berliere M, Gerday A, Fellah L, Leconte I Cancers (Basel). 2022; 14(16).

PMID: 36010869 PMC: 9405974. DOI: 10.3390/cancers14163876.

Current and Developing Liquid Biopsy Techniques for Breast Cancer.

Wu H, Chu P Cancers (Basel). 2022; 14(9).

PMID: 35565189 PMC: 9105073. DOI: 10.3390/cancers14092052.

References

Hrebien S, Citi V, Garcia-Murillas I, Cutts R, Fenwick K, Kozarewa I . Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann Oncol. 2019; 30(6):945-952. PMC: 6594458. DOI: 10.1093/annonc/mdz085. View

Fernandez-Garcia D, Hills A, Page K, Hastings R, Toghill B, Goddard K . Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer. Breast Cancer Res. 2019; 21(1):149. PMC: 6924016. DOI: 10.1186/s13058-019-1235-8. View

Li S, Lai H, Liu J, Liu Y, Jin L, Li Y . Circulating Tumor DNA Predicts the Response and Prognosis in Patients With Early Breast Cancer Receiving Neoadjuvant Chemotherapy. JCO Precis Oncol. 2020; 4. PMC: 7450928. DOI: 10.1200/PO.19.00292. View

Fisher B, RAVDIN R, AUSMAN R, Slack N, Moore G, NOER R . Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg. 1968; 168(3):337-56. PMC: 1387335. DOI: 10.1097/00000658-196809000-00004. View

Olsson E, Winter C, George A, Chen Y, Howlin J, Tang M . Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015; 7(8):1034-47. PMC: 4551342. DOI: 10.15252/emmm.201404913. View

Garcia J, Garcia V, Silva J, Pena C, Dominguez G, Sanchez A . Extracellular tumor DNA in plasma and overall survival in breast cancer patients. Genes Chromosomes Cancer. 2006; 45(7):692-701. DOI: 10.1002/gcc.20334. View

Jung A, Kirchner T . Liquid Biopsy in Tumor Genetic Diagnosis. Dtsch Arztebl Int. 2018; 115(10):169-174. PMC: 5881079. DOI: 10.3238/arztebl.2018.0169. View

Jacot W, Cottu P, Berger F, Dubot C, Venat-Bouvet L, Lortholary A . Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. Breast Cancer Res. 2019; 21(1):121. PMC: 6854749. DOI: 10.1186/s13058-019-1215-z. View

Garcia-Murillas I, Chopra N, Comino-Mendez I, Beaney M, Tovey H, Cutts R . Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019; 5(10):1473-1478. PMC: 6681568. DOI: 10.1001/jamaoncol.2019.1838. View

10.

Smerage J, Barlow W, Hortobagyi G, Winer E, Leyland-Jones B, Srkalovic G . Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014; 32(31):3483-9. PMC: 4209100. DOI: 10.1200/JCO.2014.56.2561. View

11.

Fehm T, Meier-Stiegen F, Driemel C, Jager B, Reinhardt F, Naskou J . Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting. Cytometry A. 2018; 93(12):1213-1219. DOI: 10.1002/cyto.a.23669. View

12.

Sharma G, Mirza S, Parshad R, Gupta S, Ralhan R . DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biol. 2012; 33(6):1837-43. DOI: 10.1007/s13277-012-0443-y. View

13.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

14.

Shaw J, Guttery D, Hills A, Fernandez-Garcia D, Page K, Rosales B . Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clin Cancer Res. 2016; 23(1):88-96. PMC: 6241844. DOI: 10.1158/1078-0432.CCR-16-0825. View

15.

Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M . Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res. 2010; 16(9):2634-45. DOI: 10.1158/1078-0432.CCR-09-2042. View

16.

Brabletz T . EMT and MET in metastasis: where are the cancer stem cells?. Cancer Cell. 2012; 22(6):699-701. DOI: 10.1016/j.ccr.2012.11.009. View

17.

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

18.

Andre F, Su F, Solovieff N, Hortobagyi G, Chia S, Neven P . Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann Oncol. 2023; 34(11):1003-1014. DOI: 10.1016/j.annonc.2023.08.011. View

19.

Tan G, Chu C, Gui X, Li J, Chen Q . The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis. Medicine (Baltimore). 2018; 97(13):e0197. PMC: 5895387. DOI: 10.1097/MD.0000000000010197. View

20.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts R . Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015; 7(302):302ra133. DOI: 10.1126/scitranslmed.aab0021. View